Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

November 23, 2020November 23, 2020

FDA Grants Fast Track Status, Rolling Review to Lumicell’s LUM Imaging System

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation with rolling review to Lumicell’s LUM Imaging System for the detection and treatment of breast cancer. Fast ... Read more

October 15, 2020October 15, 2020

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

News

Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two ... Read more

September 28, 2020September 28, 2020

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

News

When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast ... Read more

August 17, 2020August 17, 2020

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

News

The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who ... Read more

August 10, 2020August 27, 2020

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

News

The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment of patients with different forms ... Read more

July 23, 2020July 23, 2020

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

News

Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers in Europe. The CE mark ... Read more

July 16, 2020July 16, 2020

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

News

Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying ... Read more

July 6, 2020July 6, 2020

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

News

When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 ... Read more

June 15, 2020June 15, 2020

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

News

An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or ... Read more

May 21, 2020May 21, 2020

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

News

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new ... Read more